EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme

Bryan Day, Brett W Stringer, Fares Al-Ejeh, Michael J Ting, John Wilson, Kathleen S Ensbey, Paul R Jamieson, Zara C Bruce, Yi Chieh Lim, Carolin Offenhauser, Sara Charmsaz, Leanne T Cooper, Jennifer K Ellacott, Angus Harding, Lucie Leveque, Po L Inglis, Suzanne Allan, David G Walker, Martin Lackmann, Geoffrey W OsborneKum Kum Khanna, Brent A Reynolds, Jason D Lickliter, Andrew W Boyd

Research output: Contribution to journalArticleResearchpeer-review

152 Citations (Scopus)


Significant endeavor has been applied to identify functional therapeutic targets in glioblastoma (GBM) to halt the growth of this aggressive cancer. We show that the receptor tyrosine kinase EphA3 is frequently overexpressed in GBM and, in particular, in the most aggressive mesenchymal subtype. Importantly, EphA3 is highly expressed on the tumor-initiating cell population in glioma and appears critically involved in maintaining tumor cells in a less differentiated state by modulating mitogen-activated protein kinase signaling. EphA3 knockdown or depletion of EphA3-positive tumor cells reduced tumorigenic potential to a degree comparable to treatment with a therapeutic radiolabelled EphA3-specific monoclonal antibody. These results identify EphA3 as a functional, targetable receptor in GBM.
Original languageEnglish
Pages (from-to)238 - 248
Number of pages11
JournalCancer Cell
Issue number2
Publication statusPublished - 2013

Cite this